Palo Alto, California, and Melbourne, Australia – Feb 13, 2026 – Bitterroot Bio has made the strategic decision to pause clinical development of BRB-002. Based on data generated in the MATADOR trial, Bitterroot Bio is undertaking a focused optimization phase for BRB-002 to incorporate newly identified insights into CD47 biology in the cardiovascular environment. These […]